Oncology & Hematology Coding Alert
Target 236.2 for Borderline Ovarian Tumors
Question: The pathology report for our patient being investigated for ovarian cancer mentions “Serous tumor of low malignant potential (atypical proliferative serous tumor of ovary).” Can we report code 183.0 for this diagnosis? Florida Subscriber Answer: You should not use 183.0 (Malignant neoplasm of ovary). The pathology reports ‘low malignant potential.’ This type of tumor is considered a borderline malignancy and is confined to the ovary. Once removed, there is a 95-100 percent survival rate, but this type of tumor can recur in other areas, and some of them do later become invasive. ICD-10-CM: Code 183.0 splits into three options in ICD-10-CM: Hit the most appropriate code: Because it is a borderline tumor, you should think of it as a tumor of uncertain behavior, and you should report 236.2 (Neoplasm of uncertain behavior of ovary). ICD-10-CM: Again, code 236.2 splits into three options in ICD-10-CM:
Oncology & Hematology Coding Alert
- Take This Quiz To Conque Challenges In Chemotherapy Reporting
Check for procedure, medication, and diagnosis. Your medication administration coding accuracy depends on three key [...] - Diagnosis Coding:
Get Smart To Report Codes For Uncertain Diagnosis For Neoplasms
Hold claims in case pathology report confirms uncertain diagnosis; differentiate ‘uncertain’ vs ‘unspecified.’ You may [...] - Assess Your Coding Skills:
Coding Quiz Answers
List all infusions and accurately time each infusion. Kelly C. Loya, CPC-I, CHC, CPhT, CRMA, [...] - Adopt These 3 Rules To Simplify Physician Signature Requirements
Avoid any undue delays in documenting signatures. Complying with physician signature rules will help you [...] - Reader Question:
Target 236.2 for Borderline Ovarian Tumors
Question: The pathology report for our patient being investigated for ovarian cancer mentions “Serous tumor of [...] - Reader Question:
Bill for All Doses of Vaccines
Question: Our physician administered half dose of flu vaccine instead of a full dose to a [...] - Reader Question:
Cystoscopic Surveillance Does Not Guide Your Bladder Cancer Reporting
Question: Please provide directions for reporting ‘history of bladder cancer’ versus ‘bladder tumor of unspecified nature [...] - You Be the Coder:
Establish Cause for Screening Breast MRI
Question: Does Medicare pay for a screening breast MRI? Our physician is scheduling a breast MRI [...]
